This is an automatically translated article.
The drug Acitonal-35 has the main active ingredient, Risedronate sodium and other excipients in a sufficient amount. Acitonal-35 belongs to the group of antipyretic, analgesic, and anti-inflammatory non-steroid drugs. The drug is used to treat and prevent osteoporosis in postmenopausal women, maintain or increase bone mass in postmenopausal women requiring long-term treatment, and Paget's disease of bone.
1. What is Acitonal 35?
What is Acitonal 35? The drug Acitonal-35 has the main active ingredient: Risedronate sodium in the form of Risedronate sodium hemipentahydrate with a content of 35mg and other excipients in a sufficient amount. This drug belongs to the group of antipyretic, analgesic and non-steroidal anti-inflammatory drugs. The dosage form is a film-coated tablet, suitable for direct oral administration.
Acitonal-35 is used to treat and prevent osteoporosis in postmenopausal women, maintain or increase bone mass in postmenopausal women who have to be treated for a long time. Acitonal-35 is also effective in the treatment of Paget's disease of the bone, also known as osteomyelitis deformity.
2. What disease does Acitonal 35 treat?
The drug Acitonal-35 works in the treatment of the following pathologies:
Treatment and prevention of osteoporosis in postmenopausal women. Prevention of osteoporosis in postmenopausal women at increased risk of osteoporosis. Treatment to maintain or increase bone mass in postmenopausal women requires long-term treatment for 3 months or more with systemic corticosteroids with doses equivalent to prednisone > 7.5 mg/day. Treatment of Paget's disease of bone, also known as osteomyelitis deformity.
3. How to use and dosage of the drug Acitonal 35
3.1. How to use the drug Acitonal-35 The drug Acitonal-35 is prepared in the form of tablets suitable for oral use:
You should take the drug Acitonal-35 at least 30 minutes before the first meal of the day or between meals. Drink during the day at least 2 hours and at least 30 minutes before going to bed. Patients need to swallow the tablet whole, do not break, suck or chew it with 1 glass of water, about 120 ml. To make it easier for the Acitonal-35 tablet to reach the stomach, you should try to swallow the tablet whole with plenty of water in an upright position. Besides, you should not lie down for 30 minutes after taking Acitonal-35. It is important to note that the daily diet should include products containing calcium and vitamin D, specifically dairy products. If the diet is not adequate, you should supplement with preparations containing calcium and vitamin D. However, you should avoid taking vitamin D and calcium with preparations containing the active ingredient Risedronate. 3.2. Dosage of the drug The recommended therapeutic dose for adults is 1 35mg tablet, taken once a week. You should take your medicine on the same day of the week to minimize the chance of forgetting to take it.
Special populations:
For the elderly: No dose adjustment is required, because bioavailability, distribution and elimination in the elderly (> 60 years) are similar when compared with those in the elderly. young adults. For patients with renal impairment: No dose adjustment is required for patients with mild to moderate renal impairment. Contraindicated in patients with severe renal impairment with creatinine clearance < 30 ml/min. For people under 18 years of age: Acitonal-35 is not recommended because there are insufficient safety and efficacy data.
4. In case of over/forgotten dose of Acitonal-35
In case of overdose: Following oral administration of Acitonal-35, a severe overdose may lead to a decrease in serum calcium and phosphorus in some people. In addition, some people have signs and symptoms of hypocalcemia.
Treatment: You should drink milk or antacids containing magnesium, calcium or aluminum to bind risedronate sodium and reduce drug absorption. In the case of a serious overdose of Acitonal-35, the person using the drug should be taken to the hospital immediately. The treating physician will prescribe gastric lavage to remove unabsorbed drug or may administer calcium intravenously to restore ionized calcium, reduce the signs and symptoms of hypocalcemia.
In case of forgetting a dose of Acitonal-35: You should take one pill of Acitonal-35 as soon as you remember it in the morning and then still take one pill a week on a certain day of the week as chosen from the beginning. You should note that absolutely do not take two tablets in the same day to make up for the missed pill.
5. Undesirable effects of the drug Acitonal 35
When using Acitonal-35, you may experience some unwanted effects, specifically as follows:
Central nervous system disorders: headache, dizziness, dizziness, insomnia. Eye disorders: less common such as iritis, uveitis. Gastrointestinal disorders: Common undesirable effects such as constipation, indigestion, nausea, vomiting, abdominal pain, diarrhea. Uncommon side effects: gastritis, esophagitis, dysphagia, duodenitis or esophageal ulcer. Rare side effects: glossitis, esophageal stricture. Musculoskeletal and connective tissue development disorders: Common undesirable effects: musculoskeletal pain, back pain, joint pain, arthritis, traumatic fracture. Very rare side effect: osteonecrosis of the external ear canal. Abnormalities in liver function tests may be present. Undesirable effects on the respiratory system: bronchitis, sinusitis, rhinitis, pharyngitis, cough. Some other undesirable effects may be encountered such as flu-like syndrome, asthenia, neck pain, chest pain, allergies, hypertension, peripheral edema, skin rash, cataracts, gland hyperplasia benign prostatic hyperplasia, kidney stones, cardiac arrhythmias or urinary tract infections.
6. Interactions of the drug Acitonal 35
Interactions of Acitonal 35 may occur as follows:
Concomitant administration of Acitonal 35 with drugs containing multivalent cations (such as calcium, magnesium, iron and aluminum) may interfere with the absorption of Risedronate. These medications should be taken at a different time of day that does not coincide with Risedronate. Acitonal 35 can be used concurrently with an estrogen supplement if carefully considered. Acitonal 35 is not metabolized in the body, does not induce P450 enzymes and is less protein bound. Acetylsalicylic acid or non-steroidal anti-inflammatory, antipyretic, or analgesic drugs or NSAIDs: Among regular users of acetylsalicylic acid or NSAIDs (3 days or more per week) the incidence of adverse events in the pathway gastrointestinal tract in people treated with Acitonal 35.
7. Contraindications of the drug Acitonal 35
Acitonal 35 is contraindicated for use in the following cases:
People with a history of hypersensitivity or hypersensitivity to the active substance Risedronate sodium or to any of its ingredients. People with hypocalcemia or low blood calcium levels. Severe renal impairment with creatinine clearance < 30 ml/min. Abnormalities in the esophagus, such as stricture or inability to dilate. People with movement disorders or inability to stand or sit steadily for at least 30 minutes. Pregnant women or those who are breastfeeding. The target audience is children and adolescents.
8. Some notes when using the drug Acitonal 35
During the use of Acitonal 35, patients should note:
Food, drinks (unless drinking plain water) and preparations containing calcium, magnesium, and aluminum may interfere with the absorption of Acitonal 35. . Therefore, you must not use it at the same time as taking the medicine. Patients should take Acitonal 35 at least 30 minutes before starting their first meal of the day, or at least 2 hours apart from meals and at least 30 minutes before going to bed. Certain medications, such as bisphosphonates, have a risk of causing esophageal ulcers. Therefore, you should follow the instructions for use of the drug. Hypocalcaemia should be treated before initiating therapy with Acitonal 35. Other disorders of bone and mineral metabolism, such as parathyroid dysfunction and vitamin D deficiency, should be treated concomitantly with Acitonal 35. Caution should be exercised in people with metabolic disorders involving lactose, galactose, glucose, maltose, sucrose and fructose. The reason is that the drug contains the active ingredient Lactose. Before initiating the use of Acitonal 35 for the treatment and prevention of glucocorticoid-induced osteoporosis, the gonadal steroid hormone status of both men and women should be determined and appropriate replacement considered. The use of Acitonal 35 is not recommended in patients with severe renal impairment with creatinine clearance < 30 ml/min. Use in pregnant or lactating women: Animal studies have shown that Acitonal 35 can cause abnormalities in the skeleton of the fetus, so this drug should not be used in pregnant women. and breast-feeding. Using the drug when driving or operating machinery: Acitonal 35 can cause headache with dizziness. Therefore, when using the drug you should not participate in these activities. In summary, the drug Acitonal-35 has the main active ingredient, Risedronate sodium and other excipients in a sufficient amount. Acitonal-35 belongs to the group of antipyretic, analgesic, and anti-inflammatory non-steroid drugs. The drug is used to treat and prevent osteoporosis in postmenopausal women, maintain or increase bone mass in postmenopausal women requiring long-term treatment, and Paget's disease of bone.
To ensure effective treatment and avoid unwanted side effects, patients need to strictly follow the instructions of the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
